DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer

• DOI: 10.1007/s00066-024-02202-0
• Publication Date: 2024-03-15T13:01:41Z
• Authors: Kai J. Borm; Sophie T. Behzadi; Juliane Hörner-Ri...; David Krug; Rene Baumann; Stefanie Corradini; Marciana Nona Duma; Jürgen Dunst; Gerd Fastner; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Christiane Matuschek; Marc D. Piroth; Leonard Christoph...; Rainer Souchon; Vratislav Strnad; Wilfried Budach; Stephanie E. Combs
• Keywords: 0301 basic medicine; Brain Neoplasms; Breast Neoplasms; Review Article; Radiosurgery; ddc:; 03 medical and health sciences; Humans; Female; Cranial Irradiation; Neoplasm Recurrence, Local; Meningeal Carcinomatosis; Review Article ; Molecular profile ; Radiosurgery ; Whole-brain radiotherapy ; Craniospinal irradiation ; Neurocognitive side effects

Abstract Purpose The aim of this review was to evaluate the existing evidence for radiotherapy for brain metastases in breast cancer patients and provide recommendations for the use of radiotherapy for brain metastases and leptomeningeal carcinomatosis.

Materials and methods For the current review, a PubMed search was conducted including articles from 01/1985 to 05/2023. The search was performed using the following terms: (brain metastases OR leptomeningeal carcinomatosis) AND (breast cancer OR breast) AND (radiotherapy OR ablative radiotherapy OR radiosurgery OR stereotactic OR radiation).

Conclusion and recommendations Despite the fact that the biological subtype of breast cancer influences both the occurrence and relapse patterns of breast cancer brain metastases (BCBM), for most scenarios, no specific recommendations regarding radiotherapy can be made based on the existing evidence. For a limited number of BCBM (1–4), stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (SRT) is generally recommended irrespective of molecular subtype and concurrent/planned systemic therapy. In patients with 5–10 oligo-brain metastases, these techniques can also be conditionally recommended. For multiple, especially symptomatic BCBM, whole-brain radiotherapy (WBRT), if possible with hippocampal sparing, is recommended. In cases of multiple asymptomatic BCBM (≥ 5), if SRS/SRT is not feasible or in disseminated brain metastases (> 10), postponing WBRT with early reassessment and reevaluation of local treatment options (8–12 weeks) may be discussed if a HER2/Neu-targeting systemic therapy with significant response rates in the central nervous system (CNS) is being used. In symptomatic leptomeningeal carcinomatosis, local radiotherapy (WBRT or local spinal irradiation) should be performed in addition to systemic therapy. In patients with disseminated leptomeningeal carcinomatosis in good clinical condition and with only limited or stable extra-CNS disease, craniospinal irradiation (CSI) may be considered. Data regarding the toxicity of combining systemic therapies with cranial and spinal radiotherapy are sparse. Therefore, no clear recommendations can be given, and each case should be discussed individually in an interdisciplinary setting.